Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Inclusion Criteria: * 1\. Extensive stage small cell lung cancer proved by pathology. * 2\. Extensive small cell lung cancer does not receive systematic treatment. * 3\. limited SCLC patients have received radiotherapy and chemotherapy for more than 6 months. * 4\. patients have measurable lesions according to RECIST version 1.1. * 5\. Male or female who is 18 to 75 years old. * 6\. ECOG PS 0 or 1. * 7\. Life expectancy is more than12 weeks. * 8\. Appropriate organ system function. * 9\. hyroid-stimulating hormone is ULN or less (If T3 and T4 is normal, he still meets the Inclusion Criteria even the abnormal TSH. ) * 10\. Take proper contraceptive measures. * 11\. Subjects voluntarily participate in this study and sign the informed consent. Exclusion Criteria: * 1\. Previous treatment with apatinib, anti-programmed cell death (PD-1), anti-PD-1, or other PD-1/ PD-L1 immunotherapy. * 2\. Cancer meningitis. * 3\. patients had been diagnosed and/or treated for other malignancies within 5 years prior to enrollment, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix. * 4\. There are many factors affecting oral medication, such as inability to swallow, post-gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.. * 5\. Uncontrollable pleural effusion, pericardial effusion or ascites, requiring repeated drainage. * 6\. Patients with spinal cord compression who were not cured or relieved by surgery and/or radiotherapy, or who were diagnosed with spinal cord compression after treatment and without clinical evidence of stable disease ≥1 week before enrollment; * 7\. Patients with hypertension who cannot be well controlled by oral antihypertensive therapy, suffer from myocardial ischemia or myocardial infarction of grade I or above, arrhythmias of grade I or above , or cardiac insufficiency; * 8\. Subjects had signs of bleeding, hemoptysis, or a history of unhealed wounds, ulcers, fractures within 2 months prior to initial administration. * 9\. The adverse events caused by previous treatment did not completely recover. * 10\. Patients with major surgery or obvious traumatic injury within 28 days before enrollment; * 11\. Occurred arterial or venous thromboembolism events within 6 months. * 12\. People with a history of drug abuse or mental disorders. * 13\. Suffering from a serious and/or uncontrollable disease; * 14\. Vaccination or attenuated vaccine received within 4 weeks. * 15\. Severe allergies that require treatment with other monoclonal antibody drugs; * 16\. Active autoimmune disease requiring systemic treatment within 2 years prior to the first administration; * 17\. Immunosuppressive therapy with systemic or absorbable local hormones and continued for 2 weeks after the first dose; * 18\. Participate in other anticancer drug clinical trials within 4 weeks; * 19\. In the investigator's judgment, there are other factors that may have led to the termination of the study.